Clinical Trial Results: ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating FAK kinase inhibitor to re-sensitize carboplatin-resistant ovarian cancer; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Snippet

Sponsor: Michael McHale | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-07-31